Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yarrow BioscienceYARW -2.78%13 Cash Ratio is 14.87 as of Jun. 2026, which is at its 10-year median of 14.87. GuruFocus rates YARW with a GF Score™ of 13/100. Among 1,380 Biotechnology companies, Yarrow Bioscience ranks better than 88.55% on this metric.
Yarrow Bioscience has a Cash Ratio of 14.87. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Yarrow Bioscience's Cash Ratio or its related term are showing as below:
YARW'
s Cash Ratio Range Over the Past 10 Years
Min: 1.4 Med: 14.87 Max: 17.26
Current: 14.87
During the past 1 years, Yarrow Bioscience's highest Cash Ratio was 17.26. The lowest was 1.40. And the median was 14.87.
YARW's Cash Ratio is ranked better than 88.55% of 1380
companies
in the Biotechnology industry
Industry Median: 2.96
vs YARW: 14.87
Yarrow Bioscience (NAS:YARW) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Yarrow Bioscience Cash Ratio Related Terms
Yarrow Bioscience Cash Ratio Historical Data
* Premium members only.
The historical data trend for Yarrow Bioscience's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience Cash Ratio Chart
Yarrow Bioscience Annual Data
Trend
Dec25
Cash Ratio
1.40
Yarrow Bioscience Quarterly Data
Jun25
Dec25
Mar26
Jun26
Cash Ratio
0.00
1.40
17.26
14.87
YARW vs CGTX, RANI, VRCA: Cash Ratio Comparison
For the Biotechnology subindustry, Yarrow Bioscience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yarrow Bioscience Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Yarrow Bioscience's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a Cash Ratio of 14.87 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Yarrow Bioscience and its competitors. This is near median its historical median of 14.87. Over the past decade, Yarrow Bioscience's Cash Ratio has ranged from 1.40 to 17.26. According to the industry distribution chart, Yarrow Bioscience ranks #158 out of 1380 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Yarrow Bioscience's Cash Ratio too high?
Yarrow Bioscience's current Cash Ratio of 14.87 is near median its 10-year median of 14.87. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 17.26. The Biotechnology industry median Cash Ratio is 2.96. Yarrow Bioscience's value of 14.87 is 402.4% above this industry median. Based on the distribution chart, Yarrow Bioscience ranks #158 out of 1380 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's Cash Ratio compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #158 out of 1380 companies for Cash Ratio. This places Yarrow Bioscience in the top 11% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. Yarrow Bioscience's value of 14.87 is 402.4% above this benchmark. Historically, Yarrow Bioscience's own Cash Ratio has ranged from 1.40 to 17.26 over the past decade. While the company's 10-year median is 14.87 vs. the industry median of 2.96, Yarrow Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,380 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yarrow Bioscience's current Cash Ratio of 14.87 is 402.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current Cash Ratio is 14.87, which is near median its own 10-year median of 14.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current Cash Ratio of 14.87. The current Cash Ratio is 14.87, which is near median its 10-year median of 14.87 and 402.4% above the Biotechnology industry median of 2.96. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current Cash Ratio is 14.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
